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Abstract
Recent studies have highlighted the importance of interconnectivity in a large range of molecular and human disease-
related systems. Network medicine has emerged as a new paradigm to deal with complex diseases. Connections between
protein complexes and key diseases have been suggested for decades. However, it was not until recently that protein
complexes were identified and classified in sufficient amounts to carry out a large-scale analysis of the human protein
complex system. We here present the first systematic and comprehensive set of relationships between protein complexes
and associated drugs and analyzed their topological features. The network structure is characterized by a high modularity,
both in the bipartite graph and in its projections, indicating that its topology is highly distinct from a random network and
that it contains a rich and heterogeneous internal modular structure. To unravel the relationships between modules of
protein complexes, drugs and diseases, we investigated in depth the origins of this modular structure in examples of
particular diseases. This analysis unveils new associations between diseases and protein complexes and highlights the
potential role of polypharmacological drugs, which target multiple cellular functions to combat complex diseases driven by
gain-of-function mutations.
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Introduction
The complex interweave of interactions between proteins plays
a key role for many cellular processes. Protein complexes emerge
as temporally stable compounds to perform precise biological
functions through the association of proteins by means of non-
covalent protein-protein interactions. The fact that relatively
similar genome sizes give rise to drastically different organism’s
complexity [1] has raised the question of what mechanisms
constrain the huge number of possible protein complexes [2–4].
On the other hand, the information on protein-protein interac-
tions and protein complex formation does not only provide a
better understanding of molecular evolution [5], but it may also
improve our knowledge of human disorders and lead to new
strategies for therapeutic intervention.
Since the number of discovered single-target drug is not
increasing as fast as could be expected based on our current
knowledge of the genome, several novel approaches have been
suggested such as the development of multi-target drugs. One of the
drawbacksforthe fastdevelopmentofsuchdrugsisthat itisnoteasy
to experimentally test the response of a complex system to a multi-
target drug, unless in vivo experiments are performed. But beyond
experimentalconstraints, several workshave suggested that multiple
but partial attacks on specific targets can be more efficient that the
knockout of a single target [6]. In Ref. [7], several studies on human
system-drug interactions were discussed. Drug-target networks have
recently been extensivelyinvestigated[8–11].Moreover, the human
disease-gene network was reported in [12], and the interactions
between therapy and drugs at different ATC levels studied in [13].
The regulation of drug targets by miRNA was also extensively
analyzed [14]. But in spite of their importance, the intricate web of
interactions defined by the human associationsof proteincomplexes
and all available drugs remains uncharacterized. This network
represents a higher level view of the interactions between drugs and
life molecules since each molecular complex is also composed of
individual proteins as subunits. As shown by Ref. [7], networks with
higher complexity could also be explored by considering drug –
symptoms and drug – patients associations.
While previous works have focused on specific complexes that
lead to human disorders, until recently protein complexes were not
identified and classified in a sufficiently comprehensive way for a
systematic analysis of the human protein complex system to be
performed. We here present a large-scale analysis of the global set
of relationships between all available drugs and human protein
target complexes. By using the resulting network, it should be
possible to elucidate to what extent complexes interact with drugs
as well as to uncover specific links between diseases and protein
complexes. Related approaches have dealt with the problem of
providing a global, network-based method for prioritizing disease
genes and inferring protein complex associations [15] and large-
scale disease gene discovery by identifying human protein
complexes containing known disease genes [16].
Since a first glimpse of non-random structures and dynamic
behavior was observed a decade ago, a rich variety of global
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behind complex networks [17]. Networked structures can emerge
at different levels, from single node characteristics and the
tendency of pairs of nodes to connect to each other, to the
patterns exhibited by associations of three or more nodes known as
motifs. These motifs are also assembled with each other defining
modules and communities, which constitute an intermediate scale
between single nodes and the whole networked structure.
The existence of higher order structures like modules and
communities is a signature of a non-random system and provides
insights into their functional organization [18]. A module
represents a densely connected group of nodes that, however, is
weakly connected to the remaining network. The presence of
modular structure may drastically change dynamical processes
that occur in networks. Spreading processes like virus epidemics
and synchronization strongly depend on network modularity [19].
Moreover, modularity itself is heterogeneous and modules may
have a variety of density of edges, sizes and structural features in
general [20]. This large variety of features and patterns makes the
detection of modularity an important albeit challenging problem.
In this work, we focus on a network that combines protein
functionality information with drug interactions, in an attempt to
unveil new strategies and structural features to combat complex
diseases. Proteins interact with each other and define protein
complexes. Protein complexes have a rich variety of functions in
cells and play a key role in many human disorders. However, in
spite of their importance, network studies based on protein
complexes in human are still lacking. Moreover, an investigation
of the interactions between all available drugs and all discovered
protein complexes has not been attempted to our knowledge. The
existence of modularity in this bipartite graph may lead to develop
new strategies to deal with key diseases from a systemic point of
view, shifting the focus from targeting individual genes or proteins
to disrupting protein complexes formation. It is worth noticing,
however, that several works have investigated protein complexes
networks in model organisms such as yeast [21,22]. Authors used
an integrative approach in the context of gene association studies.
In contrast, here we focus on human protein complex and drug
associations and our methodology relies on module identification
via maximization of a modularity objective function.
We used a simulated annealing algorithm to identify modules in
the protein complex – drug network. The principle of this
algorithm is to maximize the modularity using simulated annealing
in an attempt to find low-cost configurations of structures without
being trapped by high-cost local minima [23]. The algorithm
mimics the cooling process of a material to improve its crystal
structure. Although there have been several suggested algorithms
for maximizing a modularity objective function, we selected a
simulated annealing-based algorithm because it offers the highest
accuracy in the detection of modularity in bipartite networks
comprising up to a few thousands of nodes [24]. In very large
networks, faster algorithms like greedy search, extremal optimiza-
tion or spectral methods are better suited to deal with sizes of
millions of nodes [18,25]. See also the reviews [20,26] for a
detailed description of the state-of-the art in community detection.
The algorithm was able to detect modules in the protein complex
– drug network consisting of less than 1500 nodes and determine
the global average modularity. The computation of modularity
using network projections as well as the bipartite graph itself
suggests that protein complexes as well as drug networks are not
random networks and contain a rich and heterogeneous internal
structure. The network of interactions between protein complexes
and drugs reveals novel associations between key molecular
compounds and diseases. The non-randomness characteristic of
this network opens the possibility to explore the implications of the
high modularity in the protein complex – drug space in order to
unravel new pharmacological strategies. In this work, we consider
the strategy of targeting a protein complex whose mutation is
associated with a disease that results from a gain of function or
aberrant increased activity of proteins. In the case of a disease
driven by loss-of-function mutations though, additional informa-
tion will need to be incorporated with the present approach in
order to distinguish between increased or decreased activity.
Methods
Network construction
CORUM is a comprehensive database of mammalian protein
complexes [27]. Entries are manually curated and annotated,
including information on protein complex function, localization,
subunit composition, references to Entrez gene identifiers and
literature.
DrugBank is an online database of drug data, targets and action
information [28]. It includes all drugs approved by the U.S.
Federal Drugs Administration, as well as a large number of
experimental drugs. All entries are richly annotated providing
detailed information about drug chemical, pharmacological and
therapeutic properties, as well as target sequences, structures and
functions.
To construct a bipartite network of drugs and protein
complexes, we extracted the list of protein subunits for each
complex in the CORUM database, which were referenced by
their SwissProt identifier. The same operation was conducted for
all drug targets in the DrugBank database, resulting in a list of
protein targets for each drug. The total number of drug – protein
target interactions was 11950. An edge was created between a
drug and a protein complex if at least one protein target of the
drug was also a subunit of the protein complex. The resulting
bipartite network comprised 1419 nodes (680 drugs and 739
complexes) and 3690 edges.
In all our figures colors are attributed to modules on an
arbitrary basis, so that each module has a specific color. These
colors are kept consistent across all figures, so that the same
module appears with the same color in all figures. All network
visualizations were produced using the Cytoscape software [29].
Network projections
Each bipartite network composed of two types of nodes can be
projected (i.e. transformed) onto two networks, called projections
of the original bipartite network (Figure 1). Each projected
network is then composed of only one type of nodes. A bipartite
graph for protein complexes and drugs can be formally defined as
G=(P, D, E), where P is a set of protein complexes, D a set of
drugs and E a set of edges that links two nodes from D and P.
Gp=(P, Ep) represents the P-projection of the graph G in which
nodes of P are linked together if they have at least one neighbor (D)
in common in the graph G. The set of edges Ep can be defined as:
Ep~ffp,p’g ( j Ad[D) : ((d,p)[E ^ (d,p’)[D) ^ p=p’gð 1Þ
The D-projection Gd is defined dually.
Modularity in network projections
A common characteristic of proposed algorithms to identify
modularity in networks is the maximization of a modularity
function. An objective function that describes modularity is usually
based on the concept that the density of edges in the network is
highly heterogeneous. Modules are therefore specific parts of a
Protein Complex-Drug Interactions
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random expectation [18,30].
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In a given network with NM modules, the modularity can be
computed using equation 2. In this expression, L indicates the
number of edges in the network, ls is the number of edges between
nodes in the module s, and ds is the sum of degrees of the nodes in
module s. The fraction ls/L represents the fraction of edges within
a module and (ds/2L)
2 is the fraction of edges that may be inside a
module by random expectation. We used a simulating annealing
algorithm to find the set of modules (i.e. partition) that maximizes
modularity as shown in equation 2.
The algorithm is initialized by considering that each individual
node belongs to a different module (i.e. each module is composed
of exactly one node). A computational temperature T is introduced
to simulate the cooling process in materials. By starting at high
temperature the systems evolves through different modularity
stages overcoming local cost barriers. Maximizing modularity is
equivalent to minimize a cost function defined as C=2M.
At each temperature the membership of nodes is randomly
changed and updated according to the following probability: p=1
if Cf#Ci and p~exp {
Cf{Ci
T
  
if Cf.Ci where Ci and Cf are
the costs before and after updates, respectively. The cooling down
factor was set to 0.995.
Modularity in bipartite networks
It is worth mentioning that when a projection is performed, a
fraction of the information contained in the original bipartite
network is lost. In order to avoid a loss of information, the
modularity can be computed directly in the bipartite network
itself. However, in this case an alternative definition of modularity
is needed to deal with bipartite structures. As in [25], let us define
nodes of type P (protein complexes) and nodes of type D (drugs)
and consider a modularity functional form as follows:
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where tDi indicates the total number of protein complexes a drug
Di interacts with, mp indicates the number of drugs linked to the
protein complex p, and cDiDj indicates the number of protein
complexes that are simultaneously targeted by drugs Di and Dj; NM
is the number of modules and s is the module index as in equation
2. The reasoning behind equation 3 is that the average number of
protein complexes in which Di and Dj are expected to appear
together is
P
p
mp(mp{1)
P
p
mp
 ! 2 tDitDj ð4Þ
Then, using this equation, we could define the bipartite
modularity as the cumulative deviation from the random
expectation by considering that the expected number of times a
drug Di belongs to a protein complex linked to mp drugs is
mp
tDi P
p
mp.
In some cases, unweighted projections may lead to different
results since, as mentioned above, much information rooted in the
Figure 1. Example of bipartite and projected networks. (a) A bipartite sub-network extracted from the complex-drug network. (b) The drug
and protein complex projected networks. Drugs are denoted by diamonds and complexes by circles.
doi:10.1371/journal.pone.0030028.g001
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computation of modularity in the bipartite network is expected to
be more accurate than in the projections. Furthermore, besides the
highest accuracy of this algorithm for networks of a few thousands
nodes, the method is able to identify not only an optimal
attribution of the nodes into modules, but also the number of
modules and their sizes. Therefore, this algorithm was selected to
investigate the modularity of the protein complex-drug network
(composed of less than 1500 nodes) in both the bipartite networks
and their projections.
Relationships between complexes and diseases
In order to establish connections between protein complexes
and diseases, a list of Entrez gene identifiers was extracted for each
complex, as downloaded from the CORUM database. The full list
of genes associated to complexes was entered in the FunDO tool,
which searches for associations based on the Disease Ontology
[31]. This search returned a list of gene – disease associations. We
conserved all associations with a Bonferroni-corrected p-value
lower than 10
24. The list was made of 57 diseases, ranging from
cancer (246 genes, p=2 610
2109) to Down syndrome (19 genes,
p=8 610
25). All genes were eventually re-associated to the
complexes their proteins belonged to.
Results
Bipartite network of protein complexes and drugs
The bipartite network of protein complexes and drugs contains
1419 nodes (680 drugs and 739 complexes) and 3690 edges. Its
structure resembles a scale-free topology, with a small number of
nodes connected to many edges and the majority of nodes
connected to few edges (Figure 2). Hubs can be seen among both
drugs and complexes (Table 1). The most connected nodes are two
drugs, flavopiridol, which is used for the treatment of leukemia,
and vorinostat, which is used for the treatment of lymphoma, both
interacting with over 90 complexes. A number of complexes
interact with over 40 drugs, including several closely related
complexes involving ER-alpha, BKCA-beta and ESR1. The
degree of top drug hubs decreases faster but a number of drugs
interact with 20 to 40 complexes. The network data file is provided
in Information S1.
Modularity in the protein complex – drug network
Modularity is one of the emerging properties of complex
networks. Modularity is not only associated to sets of nodes with
specific structural functionalities but also plays a key role in the
dynamic behavior of systems. Modularity is also responsible for
degree correlations observed in many real-world networks.
Here, we address the problem of identifying modularity in the
bipartite protein complex – drug network. The computation of
modularity can be performed using either the bipartite graph itself
or the projected networks. Although several works have pointed
out that modularity is more reliable when computed using the
bipartite approach, we computed both results for comparison. In
general, it is expected that drugs will belong to the same module if
they share many protein targets, regardless of whether the protein
complexes themselves belong to the same module. To evaluate the
statistical significance of the modularity of each network, we
constructed an ensemble of randomized networks using a
switching algorithm [32,33]. This algorithm preserves the degree
sequence of both drugs and protein complex nodes. It randomly
selects pairs of edges, and the end points of the edges are switched
preserving the degree sequence of each node.
While the drug projection with 657 nodes shows a modularity of
0.7755 (0.145960.0010), the protein complex network with 723
nodes has a modularity of 0.6500 (0.119160.0016). Values of the
modularity and standard deviations for a trial of 20 randomized
networks with the same degree sequences as the original networks
are shown in parentheses. These values show that the analyzed
networks have a significantly higher modularity than expected by
chance. The number of modules in the drug projection is 23, while
17 modules were detected in the protein complexes projection. It is
worth noticing that in spite of the increasing density of edges in the
projected networks, the modularity is still much higher than what
we could expect in a random network. The values of modularity in
the randomized networks are still around six times lower than in
the real projected networks, giving high statistical significance to
the result in projections (p,10
230).
Network analysis shows that the drug projection is characterized
by a high mean degree ,k.=15.48 and a diameter d=7. It also
shows a small average shortest path length ,l.=2.8 and a high
mean clustering coefficient C=0.84 compatible with a small-world
network. Analysis of the protein complex projection leads to
similar values, with a slightly higher mean degree ,k.=20.7 and
diameter d=8. Similar values are found for average shortest path
,l.=2.34 and clustering degree C=0.84.
Visualizations of these projections with the identified modules
are shown in Figures S1 and S2. Moreover, we were able to
compute the modularity using the original bipartite graph. Both
projections are not extremely dense, therefore it is expected that,
in this case, both approaches should lead to similar results for the
average modularity. However, memberships of nodes as well as
the number of modules may differ. As general rule, when
projections are too dense, the computation using bipartite
graphs is preferable. The results computed in the bipartite
network show a modularity of 0.8244 and 0.7615 for drugs and
protein complexes, respectively. We obtained 48 modules of
drugs and 42 modules of complexes in the bipartite network. As
expected, the modularity values show a good correlation
between both approaches. Figure 2 shows the modules identified
in the bipartite network (mappings between database identifiers
and names of drugs and complexes are provided in Information
S2 and S3). The modularity analysis reveals that these networks
are strongly different from random networks and are character-
ized by a highly modular structure. It is worth noticing that
although the overall modularity in projected and bipartite
networks are very close, around 0.75 in average, a larger
number of modules are isolated by computation in the bipartite
graph. This is in part a consequence of the smaller number of
edges in the original bipartite graph, which tends to increase the
accuracy of module detection. For example, a large module can
potentially be more precisely identified as two weakly connected
modules. Furthermore, there is a large number of modules
composed of a single node.
Hierarchy and centrality measures
In order to get a clearer view of the identified modularity
structure, we can shrink all nodes that belong to the same module
into one node, with its size proportionate to the number of
members in the module (Figures 3 and 4). This transformation
represents a projection of the modules into a higher layer,
simplifies the structure and allows us to obtain a global view of its
hierarchy [34]. A network analysis based on centrality measures
of both complex and drug projections reveals a correlation with
node degree highlighting the non-random nature of the
modularity observed in our analysis (Figure 5). Here, we examine
the betweenness centrality (Bi) that characterizes a network
Protein Complex-Drug Interactions
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the global network architecture. It is calculated as the fraction of
shortest paths between node pairs that pass through a given node.
In contrast, the closeness centrality (Ci) measures how close a
node i is to all others in the same network and is defined as the
average mean path between a node i and all other nodes
r e a c h a b l ef r o mi t .
The distribution of betweenness centralities reveals distinctions
between a few modules occupying highly central positions and a
majority of more peripheral modules. Among modules of complexes,
the LSD1 module has a strikingly high betweenness centrality (0.42)
compared to other modules. This complex contains hubs such as the
LSD1 complex, the Kaiso-NCOR complex and the HCF-1 complex,
which have major functions in controlling the cell cycle and DNA
processing. Differences are less marked among modules of drugs, but
high betweenness centralities are exhibited by the ethylene glycol
module (0.24) and rifabutin module (0.22). The distribution of
closeness centralities is more even but again the LSD1 module
exhibits a privileged central position with a closeness centrality of
0.88. These high centrality values suggest the existence of bridging
nodes, a non-random feature of networks. Recently, this feature was
considered in detail in [35] showing that bridging nodes may play a
crucialroleinnetwork regulation. Similarly, links that bridge modules
could also be examined in detail in combination with gene expression
profiles, offering a new way to exploit the intrinsic modularity and
topological features of the drug – protein complex network.
Figure 2. Bipartite network of protein complexes and drugs, and associated modules. A drug is connected to a protein complex if at least
one protein target of the drug is also a subunit of the protein complex. Complexes are represented by circles and drugs by diamonds. Colors are
attributed to modules on an arbitrary basis, so that each module has a specific color. Drugs and protein complexes are labeled by their DrugBank and
CORUM identifier, respectively; mappings between these database identifiers and common names are provided in Information S2 and S3.
doi:10.1371/journal.pone.0030028.g002
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Drug ID Drug name Degree Complex ID Complex name Degree
DB03496 Flavopiridol 93 1004 RC during S-phase 49
DB02546 Vorinostat 91 2470 p130Cas-ER-alpha-cSrc-kinase- PI3-kinase p85-subunit 47
DB03431 Adenosine-59-Diphosphate 44 0668 BKCA-beta2AR-AKAP79 signaling 46
DB01169 Arsenic trioxide 39 0672 BKCA-beta2AR 46
DB00054 Abciximab 30 5809 GABAA receptor 46
DB00775 Tirofiban 30 1439 PTGS2 homodimer 43
DB01254 Dasatinib 25 2657 ESR1-CDK7-CCNH-MNAT1-MTA1-HDAC2 42
DB01867 Ethylene Glycol 23 2699 ER-alpha-GRIP1-c-Jun 42
DB02010 Staurosporine 22 2700 ER-alpha-c-Jun 42
DB02116 Olomoucine 22 1003 RC 41
DB02733 Purvalanol 22 2670 ER-alpha-p53-hdm2 40
DB03428 SU9516 22 5559 CDC2-CCNA2-CDK2 40
5862 CAV1-VDAC1-ESR1 40
doi:10.1371/journal.pone.0030028.t001
 
Figure 3. Projected network of complex modules. Each module of the protein complex – drug bipartite network was shrunk into a node and
the complex projection of the resulting network is represented. Modules are named according to a representative complex hub inside the module;
only names of large modules are displayed for clarity. Colors are attributed to modules on an arbitrary basis, so that each module has a specific color.
The size of nodes is proportional to the number of complexes in each module; a size scale is displayed on the right-hand side of the figure. To assign
names to condensed nodes, we chose a representative member of each module by selecting the drug with the highest degree inside the module.
doi:10.1371/journal.pone.0030028.g003
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In previous sections, we have constructed a set of functional
modules of protein complexes based on identified associations
with drugs. Since proteins linked by drug associations should in
principle be involved in related disorders, the proteins within
such modules are expected to interact preferably with one
another than with other proteins. To test this hypothesis, we
analyzed the relationship between modules of protein complexes
and a generic protein-protein interaction (PPI) network. The core
dataset of human protein-protein interactions from the Database
of Interacting Proteins (DIP, version 2010-10-10) [36] was used
as a reference. The computation of the shortest path lengths
between proteins is a measure of the proximity of proteins in a
PPI [37]; we thus use this network metric to evaluate whether the
identified modules of protein complexes have a biological
interpretation. If the proteins that belong to identified modules
appear in highly interlinked local regions of the PPI network, the
average shortest paths between these proteins would be smaller
than the average shortest path between other proteins in the PPI.
In Figure 6a, the blue curve shows the distribution of shortest
paths between proteins in the entire PPI network; the green curve
shows the distribution of shortest paths between the subset of
proteins involved in complex formation, which is only slightly
shifted towards smaller weights compared to the original
distribution; the red curve shows the distribution of shortest
paths between proteins involved in complex formation and
belonging to the same protein complex module, and the orange
curve shows the subset of these proteins belonging to the same
module but not to the same protein complex. The comparison
shows a significant shift of protein-protein pairs belonging to the
same module (red curve) towards smaller weights (p=0.001);
almost half of these proteins are adjacent in the PPI. The
observation that protein-protein pairs that are in the same
module but not in the same protein complex are also shifted
toward smaller weights (p=0.001) indicates that the shift is not
only due to protein pairs within the same complex, but also to
proteins connected through other forms of interactions. In
Figure 6b, we furthermore compare the average shortest path
in the latter network to a random control of 100 networks of the
same size preserving the degree distribution; the observed
characteristic shortest path between proteins belonging to the
same module (red arrow, 1.942) is significantly smaller than the
expected value for the random control (p=0.003). These findings
highlight the biological significance of modules identified in the
protein complex – drug network.
Figure 4. Projected network of drug modules. Each module of the protein complex – drug bipartite network was shrunk into a node and the
drug projection of the resulting network is represented. Modules are named according to a representative drug hub inside the module. Colors are
attributed to modules on an arbitrary basis, so that each module has a specific color. The size of nodes is proportional to the number of drugs in each
module; a size scale is displayed on the right-hand side of the figure. To assign names to condensed nodes, we chose a representative member of
each module by selecting the complex with the highest degree inside the module. In the case of protein complex names formed by association of
numerous protein names, we selected the protein occurring most frequently in complexes connected to the complex of highest degree.
doi:10.1371/journal.pone.0030028.g004
Protein Complex-Drug Interactions
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30028Relationships to diseases
Since the modularity analysis in the protein complex – drug
bipartite network revealed a high modularity and a striking non-
randomness, these modules are likely to be related to common
factors, in this case common diseases. To unravel the relationship
between such modules and diseases, we investigate the origin of
this modularity in two particular examples. It is important to note
that our approach is targeted towards gain-of-function mutations,
where the disease results from aberrant increased activity of
proteins.
Example 1: Leigh disease. Leigh disease is an inherited
neurometabolic disorder that affects the central nervous system,
causing degradation of motor skills and eventually death. The
disease has been linked to mutations in mitochondrial DNA,
affecting energy production and causing a chronic lack of energy
in cells [38].
The network of protein complexes connected to Leigh disease
reveals two major and clearly distinct components (Figure 7). On
the one side, a module of highly related and interconnected
protein complexes related to the respiratory chain I, connected to
anaesthetic drugs such as fluranes and halothane. On the other
side, the large CDC5L complex, formed by the assembly of 30
proteins [39]. A large number of drugs are associated to this
complex, however the association between CDC5L and Leigh
disease has not been mentioned so far. A multitherapeutic strategy
involving both targeting respiratory chain complex I and CDC5L
formations could thus be envisaged for a more comprehensive
targeting of the factors associated to Leigh disease.
Example 2: Parkinson disease. Parkinson disease is one of
the biggest health issues facing many nations with an ageing
population. It is a degenerative disorder of the central nervous
system that impairs several motor-related functions and cognitive
processes. There is no known cure for the disease, but several
drugs are used to provide relief from the symptoms. Parkinson
disease is a typical example of a complex disease, whose causes are
multifactorial and whose treatment requires new polypharma-
cological approaches [40]. Mutations of specific protein complexes
have been linked to Parkinson disease [41].
Interestingly, the network of protein complexes and drugs
connected to Parkinson disease (Figure 8) presents similar
characteristics as the Leigh disease network, albeit on a larger
scale. On the one side, a module of strongly interconnected
complexes can be observed, which are mainly linked to ESR1
and ER-alpha. These complexes are connected to a module of
about 40 drugs, including for example desogestrel, progesterone
and letrozole. On the other side, a few isolated complexes are
connected to the disease, which are themselves targeted by a large
number of drugs; these are principally the RC S-phase, RC G2/
M phase, PTGS2 homodimer, CTCF-nucleophosmin-PARP-
HIS-KPNA-LMNA-TOP and MMP-9-TIMP-1-LRP complexes.
Figure 5. Network metrics in projected networks of modules. Top panels are from the drug projection and bottom panels from the complex
projection. Left side panels represent betweenness centrality and right side panels closeness centrality.
doi:10.1371/journal.pone.0030028.g005
Protein Complex-Drug Interactions
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30028In addition, a group of 21 complexes are connected to the
disease, which are not targeted by any drug; this group includes
for example the ITGAV-ITGB1-SPP1 and the TSC1–TSC2
complexes. In this example, the network highlights a certain bias
of current pharmacological approaches, which tend to focus on a
few targets for which multiple drugs are developed, while on the
other side other potential components involved in the disease
are not targeted. More comprehensive treatments of complex
diseases such as Parkinson may require more systematic ap-
proaches attempting to target all the factors contributing to the
disease.
For example, flavopiridol is seen to be connected to five
different complexes associated to Parkinson disease, which are the
RC S-phase, RC G2/M-phase, p16-cyclin D2-CDK4, CDK8-
MED6-PARP1 and ESR1-CDK7-CCNH-MNAT1-MTA1-
HDAC2 complexes (Figure 8). Interestingly, the potential role of
flavopiridol in inhibiting cyclin-dependent kinase cdk5, which is
inappropriately elevated by neurodegenerative conditions, has
already been sug-
gested [42] but the drug is not currently used in this context.
Vorinostat, constitutes a module on its own in this network with
high betweenness centrality, highlighting its unique position as an
interactor between complexes involved in different cellular
functions, which are the DNMT1-RB1-HDAC1-E2F1, ESR1-
CDK7-CCNH-MNAT1-MTA1-HDAC2, RB1-HDAC1-BRG1
and Rb-HDAC1 complexes. So far none of these complexes was
associated to Parkinson disease; however aberrant activation of the
RB1-E2F pathway was observed to mediate neuronal cell death
and its inhibition was proposed as a possible strategy for
neuroprotection [43]. These examples show how a network
integration of heterogeneous datasets can highlight drugs with
important polypharmacological properties and offer new insights
into possible ways to combat complex diseases.
Discussion
In this work, we have considered both network projections and
the bipartite graph structure to investigate the modularity of the
complex – drug interacting space. Network projection is a useful
technique in graph theory that allows the transformation of
bipartite networks into unipartite graphs, where standard network
metrics can be easily applied. However, since real-world data are
rich in multipartite relationships, it is desirable to compute
network metrics such as modularity in the original graph. In
addition to the loss of information when a projection is performed,
each protein complex of degree k in the bipartite graph generates
k(k21)/2 edges in the drug projection in our network, which leads
to a sharp increase in edge density in the projected network [44].
This does not only makes the computation of modularity less
accurate but also drastically increases the computational time. Our
approach has been successful in considering modularity derived
from the bipartite structure.
Network analysis has provided insights into the non-random
nature of the system under study. The fact that the drug-protein
complex network is non-random has allowed us to identify
modules that can be associated to particular diseases. In a random
network, the finding of modules would not have any significance,
since each node carries almost the same topological information.
The existence of modularity implies that the network has intrinsic
features that could be exploited in future molecular therapies. The
finding that the drug – protein complex network exhibits non-
random metrics and high modularity opens a therapeutic option
when the system is linked to particular diseases.
Several recent works have analyzed the topology of a network as
a preliminary stage to consider possible medical applications. In
[45], the modularity in protein interaction networks was linked to
the prediction of breast cancer outcome. They combined
Figure 6. (a) Distribution of shortest distances in the entire protein-protein interaction network (blue curve) and in interactions between all proteins
involved in complexes (green curve); interactions between proteins involved in complexes and belonging to the same module are shown by the red
curve, and these belonging to the same module but not to the same protein complex are shown by the orange curve. (b) Observed characteristic
path length (red arrow) and distribution of characteristic path lengths for the random control (blue curve). We generated 100 independent samples
by randomly shuffling protein associations while keeping each node degree unchanged.
doi:10.1371/journal.pone.0030028.g006
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difference in modularity in two breast cancer patients. As a result,
this work encouraged the search for multi-modal therapies
targeting hubs in the network that displayed altered modularity
in disease. This example illustrates the importance of having non-
random structures in the current human interactome. In our
study, we could potentially merge our networked structure with
gene expression profiles to detect co-expression of hub partners
and perform similar analysis for several disease stages or disorders.
Additional examples of the utility of network analysis for
therapeutic approaches can be found in [46]. In general,
molecules involved in a specific biochemical process or disease
may have similar neighbors that also participate in the same or
closely related pathways or disorders. A well-defined neighbor-
hood of the interactome is then referred as a ‘‘disease module’’. In
[12], Goh et al., identified a high number of physical interactions
between the products of genes associated with the same disorder,
representing a tenfold increase relative to random expectation.
Similar observations were made in [47,48]. Analogous compar-
isons to random expectation were done in our study with drug –
complex networks. Furthermore, in our case a probabilistic
algorithm that maximizes the modularity of the whole network
identified each module as well as the global network modularity.
Identification of communities and modules is computationally
challenging and represents a central issue in network science [26].
The problem is that there are several possible definitions of
modularity and there is not yet an agreement on which one may
lead to a better representation of the same phenomena. This is
particularly true in the case of bipartite and directed networks.
One of the issues of modularity detection is the overlapping. The
existing deterministic and stochastic methods used for large
networks are able to find separated communities, whereas several
of the actual networks are made of overlapping cohesive groups of
nodes [26]. Several algorithms like CFinder [49] and ModuLand
[50] have recently been proposed to identity modules with
overlapping structure. This problem affects the nodes located at
the boundary of modules, and a node may then belong to several
modules. Farkas et al. also showed that bridging nodes may play a
crucial role in network regulation [35]. In our work, we have
focused on a bipartite network and computed the modularity in
their projected networks but also in the bipartite network itself. For
technical reasons, like the growing density of nodes in the
projections, the computation of network metrics in the bipartite
network is usually preferable [25]. Here, we have used a simulated
annealing algorithm that detects modules with high accuracy in
networks comprising up to a few thousands of nodes according to
computational experiments done in [24]. Furthermore, there is no
version of the CFinder algorithm to detect modularity with
overlapping in bipartite networks. Therefore, we did not use
CFinder for our analysis. In overlapping algorithms, some nodes
Figure 7. Tripartite network of drugs and protein complexes connected to Leigh disease. Links between the disease node and protein
complexes represent associations between genes involved in these complexes and the named disease, as specified by the Disease Ontology. Links
between protein complexes and drugs are the same as in our bipartite network, meaning that a drug is connected to a protein complex if at least one
protein target of the drug is also a subunit of the protein complex. Complexes are represented by circles and drugs by diamonds. Colors are
attributed to modules on an arbitrary basis, so that each module has a specific color. The disease node is represented by a yellow circle. The size of
nodes is proportional to the degree of each node; a size scale is displayed on the right-hand side of the figure.
doi:10.1371/journal.pone.0030028.g007
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Moreover, another issue is that there is still no consensus about a
quantitative definition of the concept of overlapping community,
and most definitions depend on the method adopted [26]. This
question could certainly be the object of further study together
with the identification of bridging nodes and links between the
determined modules. We could then examine whether the two
end-nodes of these bridging links may have any biological
importance in a similar way as done in [35].
Connections between protein complexes and diseases have been
suggested for decades [51], and several recent studies have linked
the formation of specific protein complexes to human disorders.
The Crumbs complex participates in various human diseases,
including blindness and tumour formation [52]. Alzheimer’s
disease is characterized by amyloid plaques, which are built by a
high molecular weight protein complex containing presenilin (PS),
nicastrin, Aph-1 and Pen-2 [53]; presenilins are thought to be
important drug targets for this disorder [54]. Mutations in genes
encoding structural subunits of complex I, a mitochondrial
complex involved in energy production in the form of ATP
through the process of oxidative phosphorylation, have been
identified as a cause of devastating neurodegenerative disorders
with onset in early childhood [55]. The IKK complex is an
essential regulator of NF-kappa-B activation, which is a major
regulator of the defense against pathogens, antigen-specific
adaptive immune responses or chemical stress. Dysregulated NF-
kappaB signaling was linked with the onset or progression of
various diseases, including cancer, chronic inflammation, cardio-
vascular disorders and neurodegenerative diseases [56]. Protein-
protein interactions and complex formation were also named as
highly promising drug targets for trypanosome induced diseases,
due to the low sequence identities between some parasite proteins
and human ones [57].
For those reasons, protein complexes are increasingly consid-
ered as potential targets for novel therapies to treat complex
diseases. In opposition to the predominant single drug – single
target – single disease paradigm, complexes necessarily involve
multiple proteins, thus multiplying the possibilities for disrupting
 
 
Figure 8. Tripartite network of drugs and complexes connected to Parkinson disease. Links between the disease node and protein
complexes represent associations between genes involved in these complexes and the named disease, as specified by the Disease Ontology. Links
between protein complexes and drugs are the same as in our bipartite network, meaning that a drug is connected to a protein complex if at least one
protein target of the drug is also a subunit of the protein complex. Complexes are represented by circles and drugs by diamonds. Colors are
attributed to modules on an arbitrary basis, so that each module has a specific color. The disease node is represented by a yellow circle. The size of
nodes is proportional to the degree of each node; a size scale is displayed on the right-hand side of the figure.
doi:10.1371/journal.pone.0030028.g008
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inhibitors of protein-protein interactions and this approach is
considered with interest by the pharmaceutical industry [58].
Network-based approaches can help to identify promising targets
since they enable us to consider the complete set of relationships
between protein complexes and related diseases. One of their
advantages is to reveal associations across heterogeneous datasets;
for example we have shown that vorinostat has multiple
associations with Parkinson disease which were not previously
reported although individual associations between the drug’s
targets and neuronal cell death were known. The integration of
heterogeneous datasets can highlight drugs with important
polypharmacological properties and thus offer new insights into
possible ways to combat complex diseases. We also highlighted the
non-randomness and high modularity of this network, and
described how such modules are linked to diseases. We observed
that protein pairs belonging to the same module tend to be more
closely connected through general protein-protein interactions.
Additional assessment of the biological significance of modules
could be obtained by integrating other types of high-throughput
datasets to the network, such as gene expression data.
The distinction between types of diseases driven by gain- or loss-
of-function mutation will influence drug development strategies. In
our approach, we consider the strategy of targeting a protein
complex whose mutation is associated with a disease that results
from a gain of function or aberrant increased activity of proteins.
In the case of a disease driven by loss-of-function mutations
though, additional information will need to be incorporated with
the present approach in order to distinguish between increased or
decreased activity. The application of treatment strategies without
considering this distinction could cause further inhibition of
function of an affected complex that already has a deleterious
effect. We here illustrated our strategy by the examples of Leigh
and Parkinson diseases. In the case of Leigh disease, there is
currently no known drug to treat that disease, treatments aim at
alleviating its symptoms mainly by providing thiamine or other
vitamins to stimulate mitochondrial metabolism. There is
currently no cure for Parkinson disease either, in the sense that
drugs cannot eliminate the disease but mainly slow its progression
and relieve its symptoms. Most existing anti-Parkinson drugs act as
neuroprotectants by increasing the level of dopamine or reducing
the level of acetylcholine [59]. While our approach can be
extended to other diseases, it is worth noting that targeting
functional protein complexes is only one potential aspect in the
design of therapies for complex diseases. In many cases, diseases
result from non-functional proteins, and drugs are needed that
alleviate those symptoms and not drugs that directly target those
affected proteins. Developing new therapeutic strategies involves
taking these multiple aspects into account, which is where systems
biology and tools of network medicine [46] can play a role by
providing novel approaches to integrate these vast amounts of
heterogeneous information, thereby enabling a more global
interpretation.
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network. This file can be readily imported into the Cytoscape
software for visualization by using the ‘‘Import Network from
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